24
Views
2
CrossRef citations to date
0
Altmetric
Miscellaneous

Clinical significance of anti‐citrullinated peptide antibody in Japanese patients with established rheumatoid arthritis

, , , , , , , , , , , , , , , , , , , & show all
Pages 489-490 | Received 09 Dec 2004, Accepted 17 Apr 2005, Published online: 12 Jul 2009

References

  • Dubucquoi S., Solau‐Gervais E., Lefranc D., Marguerie L., Sibilia J., Goetz J., et al. Evaluation of anti‐citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 2004; 63: 415–9
  • Sebbag M., Simon M., Vincent C., Masson‐Bessiere C., Girbal E., Durieux J. J., et al. The antiperinuclear factor and the so‐called antikeratin antibodies are the same rheumatoid arthritis‐specific autoantibodies. J Clin Invest 1995; 95: 2672–9
  • Schellekens G. A., Visser H., de Jong B. A., van den Hoogen F. H., Hazes J. M., Breedveld F. C., et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155–63
  • Rantapaa‐Dahlqvist S., de Jong B. A., Berglin E., Hallmans G., Wadell G., Stenlund H., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48: 2741–9
  • Suzuki K., Sawada T., Murakami A., Matsui T., Tohma S., Nakazono K., et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 2003; 32: 197–204
  • Kroot E. J., de Jong B. A., van Leeuwen M. A., Swinkels H., van den Hoogen F. H., et al. The prognostic value of anti‐cyclic citrullinated peptide antibody in patients with recent‐onset rheumatoid arthritis. Arthritis Rheum 2000; 43: 1831–5
  • Vencovsky J., Machacek S., Sedova L., Kafkova J., Gatterova J., Pesakova V., et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003; 62: 427–30
  • Yamanaka H., Matsuda Y., Tanaka M. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000; 43: 852–8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.